ILUSTRO: Phase 2 Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.

Samuel J Klempner Keun-Wook Lee Kohei Shitara Jean-Phillippe Metges Sara Lonardi David H Ilson Nicola Fazio Tae-Yong Kim Li-Yuan Bai Diarmuid Moran Jianning Yang Ahsan Arozullah Jung Wook Park Jeffrey J Raizer Yung-Jue Bang Manish A Shah

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Zolbetuximab plus mFOLFOX6 demonstrated promising efficacy in previously untreated patients with CLDN18.2-positive G/GEJ adenocarcinoma. These data support the first-line development of zolbetuximab in patients whose tumors are CLDN18.2 positive. Across cohorts, zolbetuximab treatment was tolerable with no new safety signals.

Keyphrases

squamous cell carcinoma
end stage renal disease
ejection fraction
newly diagnosed
small cell lung cancer
locally advanced
clinical trial
radiation therapy
big data
phase ii study
patient reported outcomes
patient reported
replacement therapy
double blind